Oui, l'âge avancé peut augmenter le risque d'anomalies chromosomiques.
ÂgeAnomalies chromosomiques
#3
Le mode de vie affecte-t-il le risque ?
Un mode de vie malsain peut augmenter le risque d'anomalies génétiques.
Mode de vieAnomalies génétiques
#4
Y a-t-il des antécédents familiaux à considérer ?
Oui, des antécédents familiaux d'anomalies peuvent augmenter le risque.
Antécédents familiauxRisque
#5
Les infections pendant la grossesse sont-elles un facteur de risque ?
Certaines infections pendant la grossesse peuvent affecter le développement chromosomique.
InfectionsGrossesse
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Composant-7 du complexe de maintenance des minichromosomes : Questions médicales les plus fréquentes",
"headline": "Composant-7 du complexe de maintenance des minichromosomes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Composant-7 du complexe de maintenance des minichromosomes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-23",
"dateModified": "2025-04-19",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Composant-7 du complexe de maintenance des minichromosomes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de maintenance des minichromosomes",
"url": "https://questionsmedicales.fr/mesh/D064110",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de maintenance des minichromosomes",
"code": {
"@type": "MedicalCode",
"code": "D064110",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.235.750"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Composant-7 du complexe de maintenance des minichromosomes",
"alternateName": "Minichromosome Maintenance Complex Component 7",
"code": {
"@type": "MedicalCode",
"code": "D064168",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Qing Yang",
"url": "https://questionsmedicales.fr/author/Qing%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China."
}
},
{
"@type": "Person",
"name": "Binhui Xie",
"url": "https://questionsmedicales.fr/author/Binhui%20Xie",
"affiliation": {
"@type": "Organization",
"name": "Department of Hepatobiliary Surgery, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China."
}
},
{
"@type": "Person",
"name": "Hui Tang",
"url": "https://questionsmedicales.fr/author/Hui%20Tang",
"affiliation": {
"@type": "Organization",
"name": "Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China."
}
},
{
"@type": "Person",
"name": "Wei Meng",
"url": "https://questionsmedicales.fr/author/Wei%20Meng",
"affiliation": {
"@type": "Organization",
"name": "Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China."
}
},
{
"@type": "Person",
"name": "Changchang Jia",
"url": "https://questionsmedicales.fr/author/Changchang%20Jia",
"affiliation": {
"@type": "Organization",
"name": "Cell-gene Therapy Translational Medicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Lenalidomide induced pneumonitis.",
"datePublished": "2022-09-07",
"url": "https://questionsmedicales.fr/article/36071644",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10781552221124533"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36052569",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cam4.5198"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.",
"datePublished": "2023-04-07",
"url": "https://questionsmedicales.fr/article/37127471",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clml.2023.03.016"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.",
"datePublished": "2023-07-25",
"url": "https://questionsmedicales.fr/article/37491332",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41408-023-00882-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36602034",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pbc.30190"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Nucléoprotéines",
"item": "https://questionsmedicales.fr/mesh/D009698"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines chromosomiques nonhistones",
"item": "https://questionsmedicales.fr/mesh/D002868"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines de maintenance des minichromosomes",
"item": "https://questionsmedicales.fr/mesh/D064110"
},
{
"@type": "ListItem",
"position": 7,
"name": "Composant-7 du complexe de maintenance des minichromosomes",
"item": "https://questionsmedicales.fr/mesh/D064168"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Composant-7 du complexe de maintenance des minichromosomes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Comment diagnostiquer une anomalie du Composant-7 ?\nQuels tests sont utilisés pour évaluer le Composant-7 ?\nY a-t-il des marqueurs spécifiques pour le Composant-7 ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels symptômes peuvent indiquer un problème avec le Composant-7 ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Lenalidomide#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Quels sont les symptômes d'une défaillance du Composant-7 ?\nPeut-on observer des symptômes cliniques ?\nLes symptômes varient-ils selon les individus ?\nY a-t-il des signes précoces d'anomalies ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Lenalidomide#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Peut-on prévenir les anomalies du Composant-7 ?\nY a-t-il des facteurs environnementaux à éviter ?\nDes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes vaccinations peuvent-elles aider ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Lenalidomide#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Quels traitements sont disponibles pour les anomalies du Composant-7 ?\nLa thérapie génique est-elle efficace ?\nDes médicaments spécifiques sont-ils utilisés ?\nLe traitement nécessite-t-il une surveillance régulière ?\nY a-t-il des effets secondaires aux traitements ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Lenalidomide#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Quelles complications peuvent survenir avec des anomalies du Composant-7 ?\nLes anomalies peuvent-elles affecter la fertilité ?\nY a-t-il des risques de maladies associées ?\nLes complications sont-elles réversibles ?\nComment les complications sont-elles traitées ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Lenalidomide#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Quels sont les facteurs de risque pour les anomalies du Composant-7 ?\nL'âge influence-t-il le risque d'anomalies ?\nLe mode de vie affecte-t-il le risque ?\nY a-t-il des antécédents familiaux à considérer ?\nLes infections pendant la grossesse sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Lenalidomide#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie du Composant-7 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent identifier des anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer le Composant-7 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de Western blot et les analyses de PCR sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour le Composant-7 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs protéiques spécifiques peuvent indiquer des dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il une biopsie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie peut être nécessaire pour des analyses plus approfondies."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec le Composant-7 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans la division cellulaire peuvent être des indicateurs."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une défaillance du Composant-7 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles de la division cellulaire et des anomalies chromosomiques."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cliniques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes cliniques peuvent apparaître, mais ils sont souvent non spécifiques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la gravité de l'anomalie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes précoces d'anomalies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes précoces peuvent inclure des retards de croissance cellulaire."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies du Composant-7 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les toxines et les radiations peut réduire les risques d'anomalies."
}
},
{
"@type": "Question",
"name": "Des dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages réguliers peuvent aider à détecter des anomalies précocement."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé cellulaire et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui affectent la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les anomalies du Composant-7 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des thérapies géniques et des médicaments ciblés."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique montre des résultats prometteurs dans certains cas."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques peuvent être utilisés pour cibler les anomalies."
}
},
{
"@type": "Question",
"name": "Le traitement nécessite-t-il une surveillance régulière ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière est essentielle pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent survenir, nécessitant une gestion attentive."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies du Composant-7 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers et des troubles génétiques."
}
},
{
"@type": "Question",
"name": "Les anomalies peuvent-elles affecter la fertilité ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent entraîner des problèmes de fertilité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des risques accrus de maladies métaboliques peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais pas toutes sont réversibles."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles traitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement des complications dépend de leur nature et de leur gravité."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies du Composant-7 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anomalies ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque d'anomalies chromosomiques."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie malsain peut augmenter le risque d'anomalies génétiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antécédents familiaux à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'anomalies peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections pendant la grossesse sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections pendant la grossesse peuvent affecter le développement chromosomique."
}
}
]
}
]
}
Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China.
Publications dans "Composant-7 du complexe de maintenance des minichromosomes" :
Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China.
Publications dans "Composant-7 du complexe de maintenance des minichromosomes" :
Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China.
Publications dans "Composant-7 du complexe de maintenance des minichromosomes" :
Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China.
Publications dans "Composant-7 du complexe de maintenance des minichromosomes" :
Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China. zhjianw2@mail.sysu.edu.cn.
Publications dans "Composant-7 du complexe de maintenance des minichromosomes" :
Department of Medical Oncology of the Eastern Hospital, The First Affiliated Hospital of Sun Yat-sen University, Zhongshan Er Road, Guangzhou, 510080, China. drliheping@163.com.
Publications dans "Composant-7 du complexe de maintenance des minichromosomes" :
Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China. fubinsh@mail.sysu.edu.cn.
Publications dans "Composant-7 du complexe de maintenance des minichromosomes" :
Iatrogenic lung injury is a very rare, albeit serious complication with antineoplastic therapy, including immunomodulatory drugs. Pneumonitis typically presents clinically with symptoms such as cough,...
We present a case in which therapy from an immunomodulatory drug, lenalidomide, elicited a pneumonitis in the form of a 9 cm lung mass. An exhaustive workup was completed to rule out viral, bacterial,...
Lenalidomide was discontinued and corticosteroid therapy was initiated. This resulted in a complete clinical and radiographic resolution of symptoms....
Several case reports of pneumonitis have been associated with immunomodulatory drug therapy, and while most of these exhibit diffuse ground-glass opacities radiographically, our patient presented with...
To compare the response and safety of Ixazomib/Lenalidomide/Dexamethasone (IRd) and Bortezomib/Lenalidomide/Dexamethasone (VRd) treatment in newly diagnosed multiple myeloma (MM)....
This was a single-center retrospective analysis in Xiangtan Central Hospital. A total of 52 newly diagnosed MM patients from June 2019 to June 2021 were enrolled and divided into the IRd (n = 21) and ...
Patients in IRd group and VRd group showed similar PFS (Log-rank p = 0.70), OS (Log-rank p = 0.61) and overall response rate (83.87% vs 90.48%, p = 0.803). In addition, patients in VRd group showed lo...
Compared to VRd regimen, IRd had the similar efficacy, better safety, and may be more convenient for patients with poor basic condition for newly diagnosed MM. This study provides an insight for physi...
Treatment of patients with multiple myeloma (MM) in first relapse remains a challenge. This phase II study combined elotuzumab (Elo) with carfilzomib, lenalidomide, and dexamethasone (KRd) for treatme...
Enrolled patients received Elo-KRd induction for 4 cycles, and Elo-lenalidomide maintenance until progression. The primary endpoint was VGPR or better (≥VGPR) postinduction. Secondary endpoints were M...
Of 15 patients enrolled, 10 (67%) had high-risk features (del17p, t[4;14], t[14;16], 1q gain/amplification, plasma cell leukemia, extramedullary MM, or functional high risk), 12 (80%) were lenalidomid...
A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated ...
Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd ...
The event-free survival of pediatric low-grade gliomas is poor, and patients often require multiple treatment strategies. While MEK and RAF inhibitors are efficacious in early-phase trials, not all pa...
Lenalidomide is a ligand of the E3 ligase substrate adapter cereblon (CRBN) that achieves its clinical effects in part by the promotion of substrate recruitment and degradation. In contrast to prior t...
Lenalidomide, an immunomodulatory drug (IMiD), is commonly used as a first-line therapy in many haematological cancers, such as multiple myeloma (MM) and 5q myelodysplastic syndromes (5q MDS), and it ...
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We inve...
In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the pat...
A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free surv...
A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous...
Symmetric drug-related intertriginous and flexural exanthema (SDRIFE) is a cutaneous drug reaction that presents with symmetrical erythema in the flexures. The reaction typically appears hours-to-days...